These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

621 related items for PubMed ID: 17030515

  • 1. Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci.
    Vouillamoz J, Moreillon P, Giddey M, Entenza JM.
    J Antimicrob Chemother; 2006 Dec; 58(6):1208-14. PubMed ID: 17030515
    [Abstract] [Full Text] [Related]

  • 2. Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations.
    Brauers J, Kresken M, Menke A, Orland A, Weiher H, Morrissey I.
    Int J Antimicrob Agents; 2007 Mar; 29(3):322-5. PubMed ID: 17204403
    [Abstract] [Full Text] [Related]

  • 3. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
    Cafini F, Aguilar L, González N, Giménez MJ, Torrico M, Alou L, Sevillano D, Vallejo P, Prieto J.
    J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
    [Abstract] [Full Text] [Related]

  • 4. Single-dose oral amoxicillin or linezolid for prophylaxis of experimental endocarditis due to vancomycin-susceptible and vancomycin-resistant Enterococcus faecalis.
    Moreillon P, Wilson WR, Leclercq R, Entenza JM.
    Antimicrob Agents Chemother; 2007 May; 51(5):1661-5. PubMed ID: 17353251
    [Abstract] [Full Text] [Related]

  • 5. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnidge JD.
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
    McKay GA, Beaulieu S, Arhin FF, Belley A, Sarmiento I, Parr T, Moeck G.
    J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical implications of vancomycin-resistant Enterococcus faecium (VRE) with VanD phenotype and vanA genotype.
    Song JH, Ko KS, Suh JY, Oh WS, Kang CI, Chung DR, Peck KR, Lee NY, Lee WG.
    J Antimicrob Chemother; 2008 Apr; 61(4):838-44. PubMed ID: 18230690
    [Abstract] [Full Text] [Related]

  • 10. Expression of glycopeptide-resistance gene in response to vancomycin and teicoplanin in the cardiac vegetations of rabbits infected with VanB-type Enterococcus faecalis.
    Lefort A, Arthur M, Depardieu F, Chau F, Pouzet C, Courvalin P, Fantin B.
    J Infect Dis; 2004 Jan 01; 189(1):90-7. PubMed ID: 14702158
    [Abstract] [Full Text] [Related]

  • 11. Multidrug-resistant Enterococcus faecium endocarditis treated with combination tigecycline and high-dose daptomycin.
    Schutt AC, Bohm NM.
    Ann Pharmacother; 2009 Dec 01; 43(12):2108-12. PubMed ID: 19887592
    [Abstract] [Full Text] [Related]

  • 12. E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin.
    Cunha BA, Mickail N, Eisenstein L.
    Heart Lung; 2007 Dec 01; 36(6):456-61. PubMed ID: 18005808
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model.
    Hall Snyder A, Werth BJ, Barber KE, Sakoulas G, Rybak MJ.
    J Antimicrob Chemother; 2014 Aug 01; 69(8):2148-54. PubMed ID: 24777900
    [Abstract] [Full Text] [Related]

  • 14. Occurrence of vancomycin-resistant enterococci in relation to the administration of glycopeptide antibiotics.
    Kolár M, Vágnerová I, Látal T, Kohnová I.
    Acta Univ Palacki Olomuc Fac Med; 1999 Aug 01; 142():69-71. PubMed ID: 10743728
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of daptomycin, vancomycin, and ampicillin-gentamicin for treatment of experimental endocarditis caused by penicillin-resistant enterococci.
    Ramos MC, Grayson ML, Eliopoulos GM, Bayer AS.
    Antimicrob Agents Chemother; 1992 Sep 01; 36(9):1864-9. PubMed ID: 1329632
    [Abstract] [Full Text] [Related]

  • 17. Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococci.
    Neudorfer K, Schmidt-Malan SM, Patel R.
    Diagn Microbiol Infect Dis; 2018 Jan 01; 90(1):58-63. PubMed ID: 29195766
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
    Leonard SN, Rybak MJ.
    J Antimicrob Chemother; 2009 Jan 01; 63(1):155-60. PubMed ID: 18984644
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Enterococcus faecalis endocarditis successfully treated with daptomycin].
    Bonnet E.
    Med Mal Infect; 2008 Dec 01; 38 Spec No 2():4-6. PubMed ID: 19185201
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.